Theravance Biopharma
Biopharmaceutical company focused on the discovery, development and commercialization of medicines for specialty respiratory diseases. Emphasizes internally discovered development programs, external collaborations, and publication of scientific work. The organization communicates corporate and clinical progress through investor and news releases.
Industries
Nr. of Employees
large (251-1000)
Theravance Biopharma
South San Francisco, California, United States
Patents
3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
US-12358931-B2
View DetailsCrystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
US-12239638-B2
View Details
3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
US-12358931-B2
View DetailsCrystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
US-12239638-B2
View DetailsProducts
Inhalation solution (commercial respiratory medicine)
Commercially available inhalation solution product developed for treatment of specialty respiratory diseases.
YUPELRI
YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Inhalation solution (commercial respiratory medicine)
Commercially available inhalation solution product developed for treatment of specialty respiratory diseases.
YUPELRI
YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Services
Internal development programs spanning discovery through commercial availability for respiratory disease medicines.
Internal development programs spanning discovery through commercial availability for respiratory disease medicines.
Expertise Areas
- Specialty respiratory therapeutics
- Drug discovery
- Clinical development program management
- Commercialization of pharmaceutical products
Key Technologies
- Inhalation drug delivery/formulation
- Preclinical drug discovery platforms
- Clinical development platforms
- Regulatory submission processes
News & Updates
Press release reporting first quarter 2026 financial results and corporate update.
Press release reporting fourth quarter and full year 2025 financial results and corporate update.
Press release announcing an agreement for acquisition by another company.
Announcement and link to the acquiring company's announcement about completion of the transaction.
Press release reporting first quarter 2026 financial results and corporate update.
Press release reporting fourth quarter and full year 2025 financial results and corporate update.
Press release announcing an agreement for acquisition by another company.
Announcement and link to the acquiring company's announcement about completion of the transaction.